erlotinib has been researched along with bx795 in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (bx795) | Trials (bx795) | Recent Studies (post-2010) (bx795) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 57 | 0 | 53 |
| Protein | Taxonomy | erlotinib (IC50) | bx795 (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.006 | |
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | 0.005 | |
| Serine/threonine-protein kinase ULK1 | Homo sapiens (human) | 0.087 | |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | 0.0295 | |
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial | Homo sapiens (human) | 0.065 | |
| Serine/threonine-protein kinase ULK2 | Homo sapiens (human) | 0.31 | |
| Cyclic GMP-AMP synthase | Homo sapiens (human) | 0.06 | |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | 0.0163 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
2 other study(ies) available for erlotinib and bx795
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |